Prothena (NASDAQ:PRTA – Get Free Report) announced its quarterly earnings results on Thursday. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.11), Briefing.com reports. Prothena had a negative net margin of 232.19% and a negative return on equity of 24.99%. The firm had revenue […]
Prothena Co. plc (NASDAQ:PRTA – Get Free Report) CAO Karin L. Walker sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 19th. The shares were sold at an average price of $69.19, for a total transaction of $345,950.00. The sale was disclosed in a legal filing with the SEC, which can […]
Prothena Co. plc (NASDAQ:PRTA – Free Report) has been given an average rating of “Moderate Buy” by the nine analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price target among […]
Prothena Co. plc (NASDAQ:PRTA – Free Report) has been given a consensus recommendation of “Moderate Buy” by the nine analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price target among analysts that […]
Prothena Co. plc (NASDAQ:PRTA – Free Report) Director Dennis J. Selkoe sold 5,000 shares of Prothena stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $67.43, for a total transaction of $337,150.00. Following the sale, the director now owns 2,845 shares in the company, valued […]